Life-changing MS drugs to stay on the PBS. So why are others under threat – and how is Trump involved?
Illustration
AI Summary
Health minister Mark Butler confirms Ocrevus, Kesimpta and Lemtrada will stay subsidised amid questions about the Pharmaceutical Benefits Scheme Get our breaking news email, free app or daily news podcast Australians living with multiple sclerosis will continue receiving cheaper access to life-changing medical treatments, after an expert advisory panel decided to maintain taxpayer subsidies for key drugs. Newsiline summarises this report from The Guardian Australia and links readers to the original publisher for the full story.
Key Points
- Original report published by The Guardian Australia.
- Newsiline stores only headline metadata, source credit, and a short summary.
- Readers are directed to the publisher for the complete article.
Why It Matters
This story may affect readers following the category, country, or source involved. Newsiline keeps the summary neutral and points to the publisher for full context.
Sources
The Guardian Australia: Read full story at source
Newsiline provides short summaries and links to publishers. It does not republish full articles.